Miltenyi Biotec acquires exclusive rights for the distribution and development of the viral transduction enhancer Vectofusin-1® from Genethon

Evry, France, and Bergisch Gladbach, Germany, September 28th, 2016 – Genethon, a leader in the field of gene therapy treatments for rare diseases, and Miltenyi Biotec, a global front-runner in cell processing and related technologies in cell therapy, have announced the execution of an exclusive license to the patents and trademarks for the development and commercialization of Vectofusin-1® by Miltenyi Biotec. As part of this agreement, Miltenyi Biotec has also acquired the right to grant sublicenses to its customers.